Newsroom

CHENGDU, Cina--(BUSINESS WIRE)--Chengdu Zenitar Biomedical Technology Co., Ltd. (Zenitar) sta sviluppando il Flonoltinib Maleato (FM), un inibitore orale di JAK2/FLT3/CDK6 per neoplasmi mieloproliferativi (MPN), compresa la mielofibrosi (MF) e la policitemia vera (PV). Zenitar ha avviato lo studio clinico randomizzato di Fase 2 FM-MF-02 (NCT07750574) negli Stati Uniti, in Canada e in Brasile per selezionare la dose di Fase 3 per pazienti affetti da MF refrattaria e mai trattata con inibitori di...

CHENGDU, Chine--(BUSINESS WIRE)--Chengdu Zenitar Biomedical Technology Co., Ltd. (Zenitar) développe le maléate de flonoltinib (FM), un inhibiteur oral de JAK2/FLT3/CDK6 pionnier destiné aux néoplasmes myéloprolifératifs (NMP), notamment la myélofibrose (MF) et la polyglobulie de Vaquez (PV). Zenitar a lancé l’étude randomisée de phase 2 FM-MF-02 (NCT07750574) aux États-Unis, au Canada et au Brésil afin de sélectionner la dose de phase 3 chez les patients atteints de MF vierges de traitement pa...

CHENGDU, China--(BUSINESS WIRE)--Die Chengdu Zenitar Biomedical Technology Co., Ltd. (Zenitar) entwickelt Flonoltinib-Maleat (FM), einen First-in-Class-JAK2/FLT3/CDK6-Hemmer zur oralen Einnahme für myeloproliferative Neoplasien (MPN), darunter Myelofibrose (MF) und Polyzythämie vera (PV). Zenitar hat die randomisierte Phase-2-Studie FM-MF-02 (NCT07750574) in den USA, Kanada und Brasilien gestartet, um die Phase-3-Dosis für JAKi-naive und refraktäre MF zu ermitteln. Die randomisierte Studie FMF-...

LOS ANGELES--(BUSINESS WIRE)--Madrigal Pharmaceuticals, Inc. ("Madrigal" or the "Company") investors who lost money may have claims to recover their losses. The Law Offices of Frank R. Cruz today announced it is investigating potential securities fraud claims on behalf of investors in Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), examining whether the Company may have violated the federal securities laws. The investigation centers on the disclosure about Madrigal Pharmaceuticals, Inc. on Novem...

CHENGDU, China--(BUSINESS WIRE)--Chengdu Zenitar Biomedical Technology Co., Ltd. (Zenitar) ontwikkelt FM (flonoltinib maleate), een uitstekende orale JAK2/FLT3/CDK6-remmer voor MPN's (myeloproliferatieve neoplasieën), waaronder MF (myelofibrose) en PV (polycythemia vera). Zenitar lanceerde een gerandomiseerde Fase 2 FM-MF-02 (NCT07750574) in de Verenigde Staten, Canada en Brazilië om Fase 3-dosis te selecteren voor JAKi-naïeve en refractaire MF. De gerandomiseerde FMF-02 (NCT06457425) voldeed a...

LOS ANGELES--(BUSINESS WIRE)--RASA World is introducing its newest live experience IP, MONUMENTS by RASA, a global series transforming iconic landmarks into one-night-only, deeply sensory experiences. Each event will reimagine a celebrated space, from cathedrals and historic civic buildings to cultural landmarks across the globe.RASA is bringing three distinct live experience IPs to San Francisco landmarks in under three months: the sold-out Pier Play festival at Pier 70 in September, MONUMENTS...

TOKYO--(BUSINESS WIRE)--John Shegerian, Chairman and CEO of ERI, the leading material resource recovery, ITAD, mobility and data destruction/processing provider and largest recycler of electronics in the US, was featured as an expert panelist on the latest advance practices in circularity yesterday at the World Remanufacturing Summit 2026 at Waseda University’s Nishi-Waseda Campus in Tokyo, Japan. In a panel moderated by Kenichiro Chinen of California State University, Sacramento, Shegerian was...

BELLEVUE, Wash.--(BUSINESS WIRE)--Auros, the human network behind AI and the company behind UserTesting and User Interviews, today announced that its UserTesting Model Context Protocol (MCP) server is available through the SpaceXSI Marketplace, giving product, design, engineering, UX, and research teams using Grok Build a direct way to bring human insight into AI-powered product development. Winning products are built on deep customer understanding. Now that coding agents let teams ship in a fr...

LIBERTYVILLE, Ill.--(BUSINESS WIRE)--Intermatic acquires Sunrise Technologies, strengthening its infrastructure lighting controls portfolio and laying a foundation for growth....

PALO ALTO, Calif.--(BUSINESS WIRE)--Astrocade, the content platform where anyone can create, share, and play games and interactive content, today announced a $100,000 winner-take-all Creator Competition. 25 creators will spend three weeks making playable content on Astrocade, and the one whose work earns the most plays wins the full prize. Applications are open now through November 20 at https://www.astrocade.com/contests/100k-creator-contest-2026. The competition is free to enter and open to th...